|Videos|March 21, 2022
The role of doublet and triplet therapies in prostate cancer
Author(s)Urology Times staff
“There are many studies now that have shown that these doublets and triplets seem to be better than just ADT alone,” says William K. Oh, MD.
Advertisement
In this video, William K. Oh, MD, discusses the rise of doublet and triplet therapies in the treatment of prostate cancer, and what questions are still being investigated related to these novel treatments.Oh is a clinical professor of medicine at the Icahn School of Medicine, Mount Sinai in New York, New York.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Sildenafil cream for female sexual arousal disorder available to prescribe in select states
2
Experts urge FDA to revisit labeling for testosterone replacement therapy in men
3
FDA approves ProVee System for benign prostatic hyperplasia
4
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
5
